Introduction:

The Hepatitis markets have high patient potential, despite declining transmission rates. In addition, the current treatments available are not efficacious in the majority of patients and, as such, both markets contain high levels of clinical unmet need. However, commercial interest in these markets has been increasing, with a relatively large number of compounds poised for HBV market entry over the next 5-7 years and the success of Schering-Plough’s PEG-Intron following its launch in 2001. 

Scope:

* Review of patient potential across the seven major markets, including patient segmentation by genotype and disease progression 

* Overview of current clinical trial design 

* In depth analysis of the HCV late-stage pipeline using current gold standard therapy to compare product efficacies 

* HBV late-stage pipeline analysis, including forecasts of key Phase III products up to 2011 

Report Highlights:

An increase in late-stage HBV antiviral product development will boost therapy rates and drive treatment regimens towards combination strategies as seen in the HIV market. This will not only reduce resistance but also potentially increase treatment efficacy, thereby boosting patient compliance and physician confidence 

The viral genotype plays an important role in determining the efficacy of interferon therapy in both HBV and HCV infections. However, while the impact of HCV genotypes have been well characterized the HBV genotype remains comparatively under-studied. Ultimately, viral genotype will play a key role in shaping the future dynamics of both markets. 

Reasons to Purchase:

* Pinpoint market niches in order to facilitate successful penetration strategies 

* Target research and development resources more effectively through an understanding of unmet needs and recent clinical trials 

* Gain an understanding of the clinical and commercial unmet needs within these indications 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a226